Novo Nordisk stock surges 7% after Ozempic maker’s latest weight-loss drug shows promise
The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger.
Novo Nordisk Stock Eyes Best Day In 17 Months On New Obesity Drug Trial Data: Retail Breathes Easy
Shares of Novo Nordisk surged over 13% in premarket trading Friday, driven by promising topline results from a early-stage trial of amycretin, a new weight-loss drug candidate. If gains hold, this could mark the stock’s best single-day performance since Aug.
Novo Nordisk Shares Surge on New Obesity Drug Results
Novo Nordisk shares rose sharply after the Danish pharmaceutical giant said an experimental weight-loss shot helped patients lose 22% of their bodyweight in a clinical trial.
Novo Nordisk Stock Jumps on Early Stage Weight-Loss Drug Trial Results
KEY TAKEAWAYS Novo Nordisk's U.S.-listed shares are surging 9% Friday morning after the Danish drugmaker reported early stage results for its amycretin weight-loss drug.The maker of Ozempic and Wegovy said that its Phase 1b/2a trial showed people achieved weight loss from a mean baseline body weight of 92.
Novo Nordisk Stock Surges On Weight Loss Drug Data and Analysts Say It's Still a Buy
Novo Nordisk stock is paring its year-over-year deficit on positive early stage trial results for the company's new weight loss drug. Here's what you need to know.
Novo Nordisk Obesity Drug Achieves Up to 22% Weight Loss in Clinical Trial
Novo Nordisk's (NVO) said Friday that its investigative weight loss drug, amycretin, led to a body weight reduction of up to 22% in an early-stage trial. The maker of obesity drug Wegovy and diabetes treatment Ozempic said its phase 1b/2a trial covered 125 overweight people.
pharmaphorum2d
Novo Nordisk launches recycling programme for pen injectors
The new PenCycle programme covers Novo Nordisk's FlexPen and FlexTouch ... an 'at home' collection service for people using growth hormone pens. "These pens are made from high-quality, ...
Nasdaq25d
Why Novo Nordisk (NVO) is a Top Growth Stock for the Long-Term
Bagsværd, Denmark-based Novo Nordisk is a global healthcare company ... The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.